ELRUSITO, abundantes noticias en SPPI el dia de hoy.... se van $30M, veamos como toman la noticia, topotarget +65%
http://finance.yahoo.com/marketupdate/inplay#sppi
registrational trial (SPPI) 4.51 : Co announces it has entered into a co-development and commercialization agreement with TopoTarget A/S for Belinostat, a novel histone deacetylase inhibitor. Belinostat is currently in a registrational trial, under a Special Protocol Assessment, as a monotherapy for relapsed or refractory Peripheral T-Cell Lymphoma, an indication in which it has been granted Orphan Drug and Fast Track designation by the FDA. Under terms of the agreement, Spectrum licensed the rights to Belinostat for North America and India, and an option for China, in exchange for an upfront cash payment of $30 mln, potential milestone payments of up to $320 mln, and one mln shares of Spectrum common stock based upon the successful achievement of certain development, regulatory and commercial milestones, as well as double-digit royalties on net sales of Belinostat. Spectrum and TopoTarget will jointly fund development activities, whereby clinical trial costs will be 70% borne by Spectrum, and 30% by TopoTarget for new trials to be initiated.